Provided by Tiger Trade Technology Pte. Ltd.

OKYO Pharma Limited

1.52
+0.02001.33%
Volume:19
Turnover:28.71
Market Cap:79.77M
PE:-6.33
High:1.52
Open:1.52
Low:1.52
Close:1.50
52wk High:3.20
52wk Low:1.34
Shares:52.48M
Float Shares:28.04M
Volume Ratio:0.02
T/O Rate:0.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2400
EPS(LYR):-0.2400
ROE:-263.78%
ROA:-43.09%
PB:6.47
PE(LYR):-6.33

Loading ...

Company Profile

Company Name:
OKYO Pharma Limited
Exchange:
NASDAQ
Establishment Date:
2007
Employees:
5
Office Location:
35a Albemarle St,Floor 2,London,Greater London,United Kingdom
Zip Code:
W1S 4JE
Fax:
- -
Introduction:
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Directors

Name
Position
Gabriele Marco Antonio Cerrone
Director and Non-Executive Chairman
Robert J. Dempsey
Chief Executive Officer and Executive Director
Bernard Denoyer
Non-Executive Director
Gary S. Jacob
Chief Development officer and Executive Director
John Brancaccio
Non-Executive Director
Willy Simon
Senior Non-Executive Director

Shareholders

Name
Position
Robert J. Dempsey
Chief Executive Officer and Executive Director
Keeren Shah
Chief Financial Officer
Flavio Mantelli
Chief Medical officer
Raj Patil
Chief Scientific Officer